IDH1 and acute myeloid leukemia: In a phase 2 study evaluating olutasidenib in patients with R/R AML with the IDH R132 mutation who had not previously received IDH1 inhibitors, the CR/CRh rate was 35% and the ORR was 48%, with notable adverse events of febrile neutropenia and cytopenia [99,103].